Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 13, 2020
Colorcon Ventures Invests in AI Solutions Provider
Author(s)Pharmaceutical Technology Editors
Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.
Advertisement
Colorcon Ventures, a corporate venture fund of Colorcon Inc., announced on August 12, 2020 that it has invested in Atomwise, a provider of artificial intelligence (AI) solutions for drug discovery.
According to a Colorcon press release, Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery. The technology currently screens libraries of more than 16 billion molecules against novel biological targets in less than two days.
“Atomwise aligns with the Colorcon Venture fund’s strategic focus on developing transformational technology solutions for the pharmaceutical industry, and Colorcon will be a strong partner for the company,” said Martti Hedman, CEO at Colorcon, in the press release. “R&D productivity is a major pain point for the pharmaceutical industry. Atomwise is the leading company using AI for small molecule drug discovery, enabling significant time and cost savings for our global customer base. We embrace Atomwise’s approach to partnering with leading pharmaceutical companies in their research and development efforts and are open to strategic alignment with our customers where appropriate.”
“We are pleased to have Colorcon Venture's support as we scale Atomwise,” added Abraham Heifets, Atomwise’s co-founder and CEO, in the press release. “With their support, we will be able to further our mission to make better medicines faster and improve the lives of billions of people.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5